BIONDVAX PHARMA/S (NASDAQ: BVXV) is one of 106 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare BIONDVAX PHARMA/S to related businesses based on the strength of its valuation, analyst recommendations, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a summary of current ratings and recommmendations for BIONDVAX PHARMA/S and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIONDVAX PHARMA/S Competitors 642 2219 5390 219 2.61

As a group, “Biological products, except diagnostic” companies have a potential upside of 36.79%. Given BIONDVAX PHARMA/S’s rivals higher possible upside, analysts clearly believe BIONDVAX PHARMA/S has less favorable growth aspects than its rivals.

Volatility & Risk

BIONDVAX PHARMA/S has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S’s rivals have a beta of 1.64, meaning that their average share price is 64% more volatile than the S&P 500.

Insider and Institutional Ownership

7.0% of BIONDVAX PHARMA/S shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 6.0% of BIONDVAX PHARMA/S shares are owned by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares BIONDVAX PHARMA/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIONDVAX PHARMA/S N/A -110.44% -68.30%
BIONDVAX PHARMA/S Competitors -5,087.90% -78.33% -24.99%

Valuation & Earnings

This table compares BIONDVAX PHARMA/S and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BIONDVAX PHARMA/S N/A -$9.96 million -2.79
BIONDVAX PHARMA/S Competitors $1.02 billion $93.10 million -4.69

BIONDVAX PHARMA/S’s rivals have higher revenue and earnings than BIONDVAX PHARMA/S. BIONDVAX PHARMA/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


BIONDVAX PHARMA/S rivals beat BIONDVAX PHARMA/S on 8 of the 9 factors compared.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.